✦ LIBER ✦

The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial

✍ Scribed by D.P. Modest; A. Jung; N. Moosmann; R.P. Laubender; C. Giessen; C. Schulz; M. Haas; J. Neumann; S. Boeck; T. Kirchner; V. Heinemann; S. Stintzing

Book ID: 112101622
Publisher: John Wiley and Sons
Year: 2011
Tongue: French
Weight: 435 KB
Volume: 131
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.26467

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cetuximab Plus Capecitabine and Irinotec

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104--A Randomized Trial of the German AIO CRC Study Group

✍ Moosmann, N.; von Weikersthal, L. F.; Vehling-Kaiser, U.; Stauch, M.; Hass, H. G 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

Impact of the Specific Mutation in KRAS

Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials

✍ Modest, Dominik P.; Brodowicz, Thomas; Stintzing, Sebastian; Jung, Andreas; Neum 📂 Article 📅 2012 🏛 S. Karger AG 🌐 English ⚖ 225 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

✍ Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Jage 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 225 KB

Effects of KRAS, BRAF, NRAS, and PIK3CA

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

✍ Wendy De Roock; Bart Claes; David Bernasconi; Jef De Schutter; Bart Biesmans; Ge 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 384 KB

Cetuximab therapy in first-line metastat

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial

✍ Adams, Richard ;Meade, Angela ;Wasan, Harpreet ;Griffiths, Gareth ;Maughan, Tim 📂 Article 📅 2008 🏛 Expert Reviews 🌐 English ⚖ 349 KB

Economic analysis of bevacizumab, cetuxi

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

✍ Lawrence, Donna; Maschio, Michael; Leahy, Kevin J.; Yunger, Simon; Easaw, Jacob 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 466 KB